Asthma and Allergy Foundation’s Post

Today is Global Chronic Rhinosinusitis with Nasal Polyps (#CRSwNP) Awareness Day. In addition to joining this podcast, AAFA published a new report called “Life with Nasal Polyps: The Patient Experience and Opportunities to Improve Care in the U.S.” https://lnkd.in/gfmEn4zN

Congratulations to Associate Professor Ashley St John on receiving a prestigious award of S$1 million from the inaugural Tanoto Foundation Medical Research Fund for her groundbreaking research on preventing the initiation of neonatal allergies. The grant has been awarded to three research projects, including Assoc Prof St John's, in order to advance the study of various medical issues and diseases prevalent in Singapore. Read more about it from the link in comments. 📸: Luther Lau, The Straits Times #DukeNUS #DukeNUSResearch #funding #allergies #medicalresearch

🔥 Hot off the Press: EUFOREA's June Newsletter is here with thrilling updates to share with you! 🔍 From exciting awareness initiatives and the CRS patient guide to upcoming events, this month's edition is packed with valuable insights and opportunities for engagement! In this edition, you'll find: 📽 Free access to the full symposium recorded at the European Parliament on 17 April 2024 on 'Raising the Bar in Respiratory Care', 🎤 Exclusive interviews with leading experts in allergy and respiratory diseases, recorded at the EUFOREA Symposium, 📺 The full episode of the Global CRSwNP Awareness Day recorded on 24 April 2024, 🧑⚕️ Newly launched #CRS Patient Pocket Guide, 💡 Newly published paper on Nasal Polyp Syndrome: A Patient-Centred Term for CRSwNP by EUFOREA, 📎 Upcoming events 2024-2025 And more news! Stay informed, stay connected, and continue to be a part of the EUFOREA community. Click below to dive into all the exciting content we've prepared for you. Happy reading! 🔗 https://lnkd.in/edGJBchU #news #newsletter #EUFOREAN #EUFOREANnewsletter #ent #physicians #respiratorycare #respiratorydiseases #nonprofit #allergies #patients #patientcare #health #healthcare #healthprofessionals #junenews #june #brussels #belgium #editorial #euforea #crswnp #nasalpolyps #nasalsyndrome

World Rabies Day: How Science Conquered a Deadly Disease On World Rabies Day (September 28th), we celebrate one of the most ground-breaking achievements in medical history—the discovery of the rabies vaccine. Rabies, which is almost always fatal once symptoms appear, is primarily transmitted through bites from infected animals, with around 99 percent of human cases resulting from rabid dogs. The turning point in the fight against rabies came in 1885, when French scientist Louis Pasteur, along with his colleague Émile Roux, began developing a weakened form of the rabies virus to create a vaccine. On July 6, 1885, a 9-year-old boy named Joseph Meister was bitten by a rabid dog. Desperate for help, his mother asked Pasteur to save her son. Pasteur made a critical and risky decision to treat the boy with his experimental vaccine, and after 14 injections over 10 days, Joseph survived. This marked a landmark moment in medicine. What makes the rabies vaccine unique is that it can be given after exposure to the virus, known as post-exposure prophylaxis (PEP). This is crucial because the rabies virus has a long incubation period, giving doctors time to act before symptoms appear. Despite this success, rabies still kills nearly 59,000 people annually, mostly in Africa and Asia. Mass dog vaccination and wider access to PEP have saved millions of lives, but more work is needed. The World Health Organization aims to eliminate dog-related rabies by 2030 through education, vaccination, and fast access to treatment. Monoclonal antibodies (mAbs) are now a key tool in PEP, providing fast, targeted defense by neutralizing the virus. Combined with the rabies vaccine, they offer immediate protection while the body builds its immune response. Unlike older treatments like rabies immune globulin (RIG), mAbs are more consistent and have fewer side effects. World Rabies Day is commemorated every year on September 28 – the anniversary of the death of Louis Pasteur – since 2007 by the Global Alliance for Rabies Control (GARC) to raise awareness about rabies prevention, highlight the importance of vaccination, and work toward the global goal of eliminating rabies. On this World Rabies Day, let us recognize how far we have come and pledge to work toward a future free from rabies. https://lnkd.in/gSRhbFfN

👏Congratulations to our Director of the Institute of Lung Health and Immunity Prof. Ali Oender Yildirim! We look forward to a successful continuation of the projects of Prof. Erika von Mutius. 👉https://lnkd.in/dzPWWWBw #helmholtzmunich #lung #Lungenforschung #therapy #research #lungdiseases #lungresearch #DZL #LHI

New publication ✍🏼📚🔍 | Today we share with you our new publication exploring the parent’s perspective of respiratory syncytial virus and subsequent wheezing burden. Respiratory Syncytial Virus (RSV) is the leading cause of hospitalization in infants. RSV bronchiolitis is associated with an increased risk of subsequent wheezing. In this online survey conducted with Sanofi, we aimed to document the parents' perception of the link between RSV infection and subsequent wheezing, wheezing-related healthcare and family resources use, and its impact on family daily life.   📊 Take a look at the study results published in Pediatric Allergy and Immunology – 2024 👉 https://lnkd.in/gVyFn6Ga Congrats 🎉 to all the authors who worked on it: Adnan Custovic, Jorge Mestre-Ferrandiz, Leyla Kragten-Tabatabaie, Julie Laurent, Laury Sellem, PhD, Mary Koslap-Petraco, DNP, PPCNP-BC, CPNP, FAANP & Chiara Cadeddu #unmetneeds #RSV #wheezing #burden #knowledgegaps EAACI PAI Journal - Pediatric Allergy and Immunology

💉 Inhalon Biopharma has been awarded a $1,020,000 grant by the Department of Health and Human Services, specifically from the National Institutes of Health's National Institute of Allergy and Infectious Diseases. This funding supports the development of IN-007, an inhaled muco-trapping immunotherapy for COVID-19 and other ACE2-targeted infections. The project aims to produce a GLP batch of IN-007, conduct IND-enabling studies, and test efficacy in vivo and ex vivo. The research, starting on 3/1/24 and lasting nearly 3 years until 2/28/27, focuses on a treatment that can be self-administered, reduces hospitalization risk, and retains activity against all variants. #SBIR #STTR #HealthInnovation #COVID19

Through my work with USISTF I have tracked international R&D opportunities open to companies from the U.S. and Israel. Though I also track international R&D Opportunities from the European Union. Here is an example of a U.S.-Finland Biomedical Research opportunity through the National Institute of Allergy and Infectious Diseases (NIAID) I'll put the link to the NOSI in the comments below. #internationalcollaboration #research #development #researchanddevelopment #biomedical #nih

Project NextGen, led by BARDA and National Institute of Allergy and Infectious Diseases (NIAID) was established to advance next-generation vaccines, therapeutics, and cutting-edge tools to improve our fight against COVID-19 and begin transforming the nation's ability to defeat future health threats. The latest BARDA publication reviews Project NextGen’s strategy against COVID-19 and shares next steps on advancing promising next-generation solutions against COVID-19. https://ow.ly/XsTF50QJBc3